Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
暂无分享,去创建一个
Sarah A. Boswell | P. Sorger | Jia-Ren Lin | J. Garber | G. Shapiro | D. Dillon | N. Tung | J. Yélamos | E. Mittendorf | S. Rodig | S. Santagata | J. Thaxton | M. Kalocsay | Matthew J. Berberich | J. Castrillon | W. Oldham | A. Mehta | Christina A. Hartl | Jennifer L. Guerriero | M. Lipschitz | Katie E. Hurst | Nathan T. Johnson | Madisson Oliwa | Emily M. Cheney | Shawn F. Johnson | Constantia Pantelidou | Aditi Kothari | Mateus de Oliveira Taveira | Anita K. Mehta
[1] H. Gelderblom,et al. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor. , 2020, Future oncology.
[2] Gennady Korotkevich,et al. Fast gene set enrichment analysis , 2019, bioRxiv.
[3] D. Stolz,et al. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ. , 2019, Immunity.
[4] G. Shapiro,et al. PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. , 2019, Cancer discovery.
[5] Wei Li,et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] L. Coussens,et al. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors , 2019, Therapeutic advances in medical oncology.
[7] Ramin Rad,et al. Web-Based Search Tool for Visualizing Instrument Performance Using the Triple Knockout (TKO) Proteome Standard. , 2018, Journal of proteome research.
[8] E. Winer,et al. Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.
[9] H. Gong,et al. Inhibition of Poly(ADP-Ribose) Polymerase Increased Lipid Accumulation Through SREBP1 Modulation , 2018, Cellular Physiology and Biochemistry.
[10] John N. Hutchinson,et al. IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization , 2018, Nature Cell Biology.
[11] W. Eiermann,et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.
[12] J. Jonkers,et al. Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors , 2018, bioRxiv.
[13] E. Coccia,et al. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth , 2018, Proceedings of the National Academy of Sciences.
[14] M. Ceppi,et al. Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis , 2018, ESMO Open.
[15] Sandro Santagata,et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes , 2018, eLife.
[16] Jennifer L. Guerriero. Macrophages: The Road Less Traveled, Changing Anticancer Therapy. , 2018, Trends in molecular medicine.
[17] S. Snyder,et al. Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases , 2018, British journal of pharmacology.
[18] Astrid Gall,et al. Ensembl 2018 , 2017, Nucleic Acids Res..
[19] A. Ashworth,et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance , 2017, bioRxiv.
[20] T. Sørlie,et al. Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. , 2017, Cancer discovery.
[21] Yi Zhang,et al. Tumor-associated macrophages, potential targets for cancer treatment , 2017, Biomarker Research.
[22] S. Takenoshita,et al. Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. , 2017, Oncology letters.
[23] Arnab Ray Chaudhuri,et al. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling , 2017, Nature Reviews Molecular Cell Biology.
[24] C. Perou,et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer , 2017, Science Translational Medicine.
[25] M. Robson,et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.
[26] Xiao-dong Zhu,et al. Colony-stimulating factor-1-induced AIF1 expression in tumor-associated macrophages enhances the progression of hepatocellular carcinoma , 2017, Oncoimmunology.
[27] A. Letai,et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages , 2017, Nature.
[28] M. Brand,et al. Quantifying intracellular rates of glycolytic and oxidative ATP production and consumption using extracellular flux measurements , 2017, The Journal of Biological Chemistry.
[29] J. Yélamos,et al. PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas , 2017, Scientific Reports.
[30] G. Hortobagyi,et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.
[31] Patrick Danaher,et al. Gene expression markers of Tumor Infiltrating Leukocytes , 2016, Journal of Immunotherapy for Cancer.
[32] Lior Pachter,et al. Differential analysis of RNA-seq incorporating quantification uncertainty , 2016, Nature Methods.
[33] P. Sorger,et al. Cyclic Immunofluorescence (CycIF), A Highly Multiplexed Method for Single‐cell Imaging , 2016, Current protocols in chemical biology.
[34] Steven P Gygi,et al. Quantitative mass spectrometry-based multiplexing compares the abundance of 5000 S. cerevisiae proteins across 10 carbon sources. , 2016, Journal of proteomics.
[35] John Kidd,et al. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Pittet,et al. The role of myeloid cells in cancer therapies , 2016, Nature Reviews Cancer.
[37] Alexey Sergushichev,et al. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation , 2016 .
[38] Eric C. Holland,et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas , 2016, Science.
[39] Lior Pachter,et al. Near-optimal probabilistic RNA-seq quantification , 2016, Nature Biotechnology.
[40] K. Moore,et al. Poly(ADP-ribose) Polymerase 1 Represses Liver X Receptor-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages* , 2016, The Journal of Biological Chemistry.
[41] Daniel J. Gaffney,et al. A survey of best practices for RNA-seq data analysis , 2016, Genome Biology.
[42] Phillip G. Popovich,et al. Novel Markers to Delineate Murine M1 and M2 Macrophages , 2015, PloS one.
[43] Peter K. Sorger,et al. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method , 2015, Nature Communications.
[44] L. Molinero,et al. Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) , 2015 .
[45] J. Blay,et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. , 2015, The Lancet. Oncology.
[46] P. Chakravarty,et al. GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. , 2015, Immunity.
[47] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] C. Ries,et al. Targeting tumor-associated macrophages in cancer therapy and understanding their complexity , 2014, Oncoimmunology.
[49] Zhongyu Yuan,et al. High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis , 2014, OncoTargets and therapy.
[50] J. Blay,et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.
[51] Edward L. Huttlin,et al. MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes , 2014, Analytical chemistry.
[52] Pornpimol Charoentong,et al. High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer , 2014, BMC Cancer.
[53] B. Kempkes,et al. Macrophage Polarisation: an Immunohistochemical Approach for Identifying M1 and M2 Macrophages , 2013, PloS one.
[54] G. Shapiro,et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance , 2013, Proceedings of the National Academy of Sciences.
[55] Y. Pommier,et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.
[56] Carl Grunfeld,et al. Mechanisms of triglyceride accumulation in activated macrophages , 2012, Journal of leukocyte biology.
[57] D. Dewitt,et al. Cellular bioenergetics is regulated by PARP1 under resting conditions and during oxidative stress. , 2012, Biochemical pharmacology.
[58] Laura J. Esserman,et al. Leukocyte composition of human breast cancer , 2011, Proceedings of the National Academy of Sciences.
[59] Karin Jirström,et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.
[60] K. Gelmon,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[61] Edward L. Huttlin,et al. A Tissue-Specific Atlas of Mouse Protein Phosphorylation and Expression , 2010, Cell.
[62] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[63] P. Allavena,et al. Tumor-Associated Macrophages (TAM) as Major Players of the Cancer-Related Inflammation , 2010 .
[64] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[65] D. Livingston,et al. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. , 2010, Carcinogenesis.
[66] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[67] P. Allavena,et al. Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation , 2009, Journal of leukocyte biology.
[68] Ruth J. Muschel,et al. A Distinct Macrophage Population Mediates Metastatic Breast Cancer Cell Extravasation, Establishment and Growth , 2009, PloS one.
[69] P. Borst,et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.
[70] J. Pollard,et al. Macrophages define the invasive microenvironment in breast cancer , 2008, Journal of leukocyte biology.
[71] P. Allavena,et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.
[72] L. Coussens,et al. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007, Breast Cancer Research.
[73] J. Peterse,et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer , 2007, Proceedings of the National Academy of Sciences.
[74] Lisa M. Coussens,et al. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007 .
[75] J. Pollard,et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. , 2006, Cancer research.
[76] Martin Kuiper,et al. BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks , 2005, Bioinform..
[77] P. Garnier,et al. NAD+ repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes. , 2003, Biochemical and biophysical research communications.
[78] F. Kishi,et al. Functional heterogeneity of colony‐stimulating factor‐induced human monocyte‐derived macrophages , 2006, International journal of hematology.
[79] F. Apiou,et al. PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase* , 1999, The Journal of Biological Chemistry.
[80] W. Wiktor-Jedrzejczak,et al. Hematological characterization of congenital osteopetrosis in op/op mouse. Possible mechanism for abnormal macrophage differentiation , 1982, The Journal of experimental medicine.
[81] P. Lane,et al. Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse. , 1976, The Journal of heredity.